Results 11 to 20 of about 130,723 (312)

Pharmacological studies on a synthetic protease inhibitor, FUT-175. I. Effects on complements and kallikrein.

Japanese Journal of Pharmacology, 1983
Abstract FUT-175 has been reported by S.Fujii et al.1) to inhibit strongly Clr, Cls, trypsin and thrombin as well as kallikrein and plasmin. In the present study, effects of FUT-175 on the complement and kallikrein system were investigated in vitro and in vivo.
Masayuki Ozeki, Minoru Oda, Yoshitaka Ino, Akemi Motoyoshi, Mitsunobu Fujita, Takuo Aoyama, Setsuro Fujii   +6 more
openalex   +3 more sources

In silico screening of phenylethanoid glycosides, a class of pharmacologically active compounds as natural inhibitors of SARS-CoV-2 proteases

Computational and Structural Biotechnology Journal, 2023
Since the advent of Covid-19, several natural products have been investigated regarding their in silico interactions with SARS-CoV-2 proteases - 3CLpro and PLpro, two of the most important pharmacological targets for antiviral development. Phenylethanoid glycosides (PG) are a class of natural products present in important medicinal plants and a drug ...
Caio Cheohen, Maria Eduarda Alves Esteves, Thamirys Silva da Fonseca, Carla Monteiro Leal, Fernanda de Lemos Fernandes Assis, Mariana Freire Campos, Raianne Soares Rebelo, Diego Allonso, Gilda Guimarães Leitão, Manuela Leal da Silva, Suzana Guimarães Leitão   +10 more
openalex   +4 more sources

Pharmacologic Optimization of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors (POPIN)-A Randomized Controlled Trial of Therapeutic Drug Monitoring and Adherence Support

JAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
We evaluated the feasibility and effectiveness of therapeutic drug monitoring (TDM) and adherence support (collectively, AT) vs standard of care (SOC) in patients receiving HIV protease inhibitors (PIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) within a nurse-led clinic. Primary end points were failure to achieve viral load of
Saye Khoo, Judith Lloyd, Mark Dalton, Alec Bonington, Elizabeth A. Hart, Sara Gibbons, P J Flegg, John F. Sweeney, E.G.L. Wilkins, David Back   +9 more
openalex   +4 more sources

Data from A Pharmacologic Inhibitor of the Protease Taspase1 Effectively Inhibits Breast and Brain Tumor Growth [PDF]

, 2023
<div>Abstract<p>The threonine endopeptidase Taspase1 has a critical role in cancer cell proliferation and apoptosis. In this study, we developed and evaluated small molecule inhibitors of Taspase1 as a new candidate class of therapeutic modalities.
David Y. Chen, Yi Shan Lee, Brian A. Van Tine, Adam C. Searleman, Todd D. Westergard, Han Liu, Ho-Chou Tu, Shugaku Takeda, Yiyu Dong, David Piwnica‐Worms, Kyoung Joon Oh, Stanley J. Korsmeyer, Ann Hermone, Richard Gussio, Robert H. Shoemaker, Emily H. Cheng, James J. Hsieh   +16 more
openalex   +2 more sources

Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors

AIDS, 2000
Pascal Clayette, Sylvie Jorajuria, Dominique Dormont   +2 more
  +9 more sources

Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties

Chemical Science, 2021
SARS-CoV-2, the cause of the COVID-19 pandemic, exploits host proteins for viral entry into human lung cells and is blocked by otamixaban in combination with a covalent protease inhibitor.
Tim Hempel, Katarina Elez, Nadine Krüger, Lluı́s Raich, Jonathan H. Shrimp, Olga Danov, Danny Jonigk, Armin Braun, Min Shen, Matthew D. Hall, Stefan Pöhlmann, Markus Hoffmann, Frank Noé   +12 more
openalex   +9 more sources

Proteases and their inhibitors as pharmacological drugs

Japanese Journal of Pharmacology, 1996
Kenji Yamamoto
openalex   +3 more sources

Insights for Future Pharmacology: Exploring Phytochemicals as Potential Inhibitors Targeting SARS-CoV-2 Papain-like Protease

Future Pharmacology
(1) Background: The SARS-CoV-2 papain-like protease (PLpro) remains an underexplored antiviral target so far. The reduced efficacy of approved treatments against novel variants highlights the importance of developing new agents. This review aims to provide a comprehensive understanding of phytochemicals as inhibitors of PLpro, identify gaps, and ...
Jawaria Jabeen, Nabeel Ahmed, Zunaira Shahzad, Maida Shahid, Taseer Ahmad   +4 more
openalex   +3 more sources

A Mini Review on New Pharmacological and Toxicological Considerations of Protease Inhibitors' Application in Cancer Prevention and Biological Research [PDF]

Asian Journal of Cell Biology, 2011
Hamid Reza Rahimi, E. Hasanli, Hossein Jamalifar   +2 more
openalex   +3 more sources

20 IN VITRO ACTIVITY AND PHARMACOLOGIC PROPERTIES OF TWO NOVEL SERIES OF HCV PROTEASE INHIBITORS

Journal of Hepatology, 2008
David N. Standring, Christophe Parsy, François-René Alexandre, Michel Derock, Frédéric Leroy, Thierry Convard, Massimiliano La Colla, L. Lallos, A. G. Loi, Chiara Musiu, Tiziana Marceddu, Barbara Poddesu, L Vargiu, Michel Liuzzi, Dominique Surleraux   +14 more
openalex   +3 more sources